Logo Prima Biomed

Welcome to the Newsroom

15 March 2017

Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston



SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) announces that the second cohort comprising six patients has now been fully recruited for its TACTI-mel (Two ACTive Immunotherapeutics in melanoma) clinical trial being conducted in Australia. Patients with unresectable or metastatic melanoma that have had a suboptimal response to KEYTRUDA® were dosed with the higher 6 mg dose of IMP321 in combination with KEYTRUDA®.